1-叠氮基-2-氟苯 | 3296-04-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-叠氮基-2-氟苯
• 英文名称: 1-azido-2-fluorobenzene
• 英文别名: 2-fluorophenyl azide；o-azidofluorobenzene
• CAS: 3296-04-6
• 化学式: C₆H₄FN₃
• mdl: MFCD09383886
• 分子量: 137.116
• InChiKey: YOBOIKMFTLTNTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  14.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2929909090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1-Azido-2-fluorobenzene solution
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Flammable liquids (Category 2), H225
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - repeated exposure (Category 1), H372
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
F Highly flammable R11
T Toxic R48/23/24/25
Xi Irritant R38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H225 Highly flammable liquid and vapour.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H372 Causes damage to organs through prolonged or repeated exposure.
Precautionary statement(s)
P210 Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P314 Get medical advice/ attention if you feel unwell.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s) F Highly flammable
T Toxic
R-phrase(s)
R11 Highly flammable.
R38 Irritating to skin.
R48/23/24/25 Toxic: danger of serious damage to health by prolonged exposure
through inhalation, in contact with skin and if swallowed.
S-phrase(s)
S16 Keep away from sources of ignition - No smoking.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Mixtures
Formula : C6H4FN3
Molecular Weight : 137,11 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
tert-Butyl methyl ether
CAS-No. 1634-04-4 Flam. Liq. 2; Skin Irrit. 2; 50 - 100 %
EC-No. 216-653-1 H225, H315
Index-No. 603-181-00-X
1-Azido-2-fluorobenzene
CAS-No. 3296-04-6 Skin Irrit. 2; Eye Irrit. 2; STOT 10 - 20 %
SE 3; STOT RE 1; H315,
H319, H335, H372
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
tert-Butyl methyl ether
CAS-No. 1634-04-4 F, Xi, R11 - R38 50 - 100 %
EC-No. 216-653-1
Index-No. 603-181-00-X
1-Azido-2-fluorobenzene
CAS-No. 3296-04-6 T, R 5 - R36/37/38 - 10 - 20 %
R48/23/24/25
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
Use water spray to cool unopened containers.

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to
form explosive concentrations. Vapours can accumulate in low areas.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and
place in container for disposal according to local regulations (see section 13).
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic
charge.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: -20 °C
Light sensitive. Over time, pressure may increase causing containers to burst
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,4 mm
Break through time: 120 min
Material tested:Camatril® (KCL 730 / Z677442, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone], test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
Complete suit protecting against chemicals, Flame retardant antistatic protective clothing, The type
of protective equipment must be selected according to the concentration and amount of the
dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: clear, liquid
Colour: light yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
Heat, flames and sparks. Extremes of temperature and direct sunlight.
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (tert-Butyl methyl ether)
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Central nervous system - (tert-Butyl methyl ether)

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting
as this material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal
company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2398 IMDG: 2398 IATA: 2398
UN proper shipping name
ADR/RID: METHYL tert-BUTYL ETHER, SOLUTION
IMDG: METHYL tert-BUTYL ETHER, SOLUTION
IATA: Methyl tert-butyl ether, SOLUTION
Transport hazard class(es)
ADR/RID: 3 IMDG: 3 IATA: 3
Packaging group
ADR/RID: II IMDG: II IATA: II
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit. Eye irritation
Flam. Liq. Flammable liquids
H225 Highly flammable liquid and vapour.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H372 Causes damage to organs through prolonged or repeated exposure.
Skin Irrit. Skin irritation
STOT RE Specific target organ toxicity - repeated exposure
STOT SE Specific target organ toxicity - single exposure
Full text of R-phrases referred to under sections 2 and 3
F Highly flammable
T Toxic
R5 Heating may cause an explosion.
R11 Highly flammable.
R36/37/38 Irritating to eyes, respiratory system and skin.
R38 Irritating to skin.
R48/23/24/25 Toxic: danger of serious damage to health by prolonged exposure through inhalation,
in contact with skin and if swallowed.
Xi Irritant
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1-叠氮基-2-氟苯 在 2-甲基十一烷-2-硫醇 、 水 、 1,1'-偶氮(氰基环己烷) 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 2-氟苯胺
  参考文献：
  名称：

  三乙基硅烷将芳族叠氮基自由基还原为胺

  摘要：

  在热条件下，在自由基引发剂的存在下，芳族叠氮化物对三乙基硅烷是惰性的，但是在额外催化量的叔十二烷硫醇的存在下，它们提供了苯胺基硅烷，因此相应的苯胺实际上具有定量收率。

  DOI：

  10.1021/jo060824k
• 作为产物：
  描述：

  2-氟碘苯 在 sodium hydroxide copper(l) iodide 、 sodium azide 、 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 以75%的产率得到1-叠氮基-2-氟苯
  参考文献：
  名称：

  通过脯氨酸促进的CuI催化的偶联反应合成芳基叠氮化物和乙烯基叠氮化物。

  摘要：

  在CuI / L-脯氨酸的催化下，芳基卤化物或乙烯基碘化物与叠氮化钠的偶联反应在相对较低的温度下进行，从而以良好或优异的产率提供芳基叠氮化物或乙烯基叠氮化物。

  DOI：

  10.1039/b400878b

文献信息

• Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold
  作者：De-pu Wang、Kai-li Liu、Xin-yang Li、Guo-qing Lu、Wen-han Xue、Xin-hua Qian、Kamara Mohamed O、Fan-hao Meng

  DOI：10.1016/j.ejmech.2020.113083

  日期：2021.2

  different target inhibitors. In this study, a series of novel indole-2-one derivatives based on 1,2,3-triazole scaffolds were synthesized for the first time, and their inhibitory activity on vascular endothelial growth factor receptor-2 (VEGFR-2) was tested. Most of the compounds had shown promising activity in the VEGFR-2 kinase assay and had low toxicity to human umbilical vein endothelial cells (HUVECs)

  在过去的五年中，我们的团队一直致力于点击化学研究，通过合成不同的目标抑制剂来探索1,2,3-三唑的生物活性。本研究首次合成了基于1,2,3-三唑骨架的一系列新型吲哚-2-酮衍生物，并测试了它们对血管内皮生长因子受体2（VEGFR-2）的抑制作用。 。大多数化合物在VEGFR-2激酶测定中显示出有希望的活性，并且对人脐静脉内皮细胞（HUVEC）毒性低。化合物13d（IC 50  = 26.38 nM）具有比舒尼替尼（IC 50）更好的激酶活性抑制能力 = 83.20 nM），对HUVEC的毒性较小。而且，它对HT-29和MKN-45细胞具有优异的抑制作用。一方面，通过试管形成分析，transwell和Western blot分析，化合物13d可以抑制HUVEC上的VEGFR-2蛋白磷酸化，从而抑制HUVEC的迁移和管形成。在体内研究中，带有VEGFR-2标记的斑马鱼模型还证实了化合物13d比
• 一种芳基叠氮类化合物的合成方法
  申请人：河南师范大学

  公开号：CN106588693B

  公开（公告）日：2019-01-18

  本发明公开了一种芳基叠氮类化合物的合成方法，具体步骤为：将碘代芳基类化合物、叠氮化钠、1,8‑二氮杂二环[5.4.0]十一碳‑7‑烯和催化剂加入到装有溶剂的反应容器中，再将反应混合物于60‑105℃搅拌反应，TLC跟踪检测至反应完全，再向反应混合物中加入氨水，然后用乙酸乙酯萃取3次，并用饱和食盐水洗1次，取有机相干燥，抽滤，旋除溶剂，柱层析纯化得到目标产物。本发明所用的原料简单易得，催化剂铜源的选择范围广，反应条件温和，操作简单，收率相对较高。
• Synthesis, antimicrobial evaluation, and in silico studies of quinoline—1H-1,2,3-triazole molecular hybrids
  作者：Paul Awolade、Nosipho Cele、Nagaraju Kerru、Parvesh Singh

  DOI：10.1007/s11030-020-10112-3

  日期：2021.11

  copper(I)-catalyzed azide-alkyne [3 + 2] dipolar cycloaddition reaction (CuAAC). Antimicrobial evaluation identified compound 16 as the most active hybrid in the library with a broad-spectrum antibacterial activity at an MIC80 value of 75.39 μM against methicillin-resistant S. aureus, E. coli, A. baumannii, and multidrug-resistant K. pneumoniae. The compound also showed interesting antifungal profile against C.

  摘要 抗菌素耐药性已成为对全球公共卫生的重大威胁，因此迫切需要具有改善治疗效果的新药。在这方面，分子杂交被认为是提供多靶点候选药物的可行策略。在此，我们报告了通过铜 (I) 催化的叠氮化物-炔烃 [3 + 2] 偶极环加成反应 (CuAAC) 合成的喹啉—1 H -1,2,3-三唑分子杂化物库。抗菌评估确定化合物16是文库中最活跃的杂合体，对耐甲氧西林金黄色葡萄球菌、大肠杆菌、鲍曼不动杆菌的 MIC 80值为 75.39 μM，具有广谱抗菌活性。和多重耐药肺炎克雷伯菌。该化合物还显示出有趣的抗白色念珠菌和新型念珠菌的抗真菌特性，MIC 80值分别为 37.69 和 2.36 μM，优于氟康唑。体外毒性分析显示对人红细胞 (hRBC) 无溶血活性，但对人胚胎肾细胞 (HEK293) 有部分细胞毒性。此外，计算机研究预测了优异的药物样特性以及三唑环在稳定与靶蛋白络合方面的重要性。总体而言，这些
• 1,2,3-Triazole–quinazolin-4(3<i>H</i>)-one conjugates: evolution of ergosterol inhibitor as anticandidal agent
  作者：Mir Mohammad Masood、Mohammad Irfan、Parvez Khan、Mohamed F. Alajmi、Afzal Hussain、Jered Garrison、Md. Tabish Rehman、Mohammad Abid

  DOI：10.1039/c8ra08426b

  日期：——

  The present study describes the synthesis of 1,2,3-triazole–quinazolinone conjugates (5a–q) from ethyl 4-oxo-3-(prop-2-ynyl)-3,4-dihydroquinazoline-2-carboxylate and phenyl azide/substituted phenyl azides employing Cu(I) catalysed Huisgen 1,3-dipolar cycloaddition. The corresponding acids (6a–q) were obtained by hydrolysis of esters (5a–q) to study the effect of these functionalities on the biological

  本研究描述了由 4-oxo-3-(prop-2-ynyl)-3,4-dihydroquinazoline-2-carboxylate 和苯基叠氮化物合成 1,2,3-三唑-喹唑啉酮共轭物 ( 5a-q )使用Cu( I )催化的Huisgen 1,3-偶极环加成的/取代的苯基叠氮化物。通过酯类 ( 5a-q )的水解获得相应的酸 ( 6a-q )，以研究这些官能团对生物活性的影响。筛选所有合成的化合物，以进行针对白色念珠菌、光滑念珠菌和热带念珠菌菌株的体外抗念珠菌评估。结果表明，化合物5n显示出有效的抗念珠菌活性，IC 50在 8.4 至 14.6 μg mL -1范围内。使用人红细胞 (hRBC) 的溶血活性和通过 MTT 测定对人胚胎肾 (HEK-293) 细胞的细胞毒性揭示了所选化合物的无毒性质。化合物5n的生长动力学研究显示了其杀菌特性，因为即使在 24 小时后也没有观察到念珠菌细
• 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
  申请人：Life & Brain GmbH

  公开号：EP2465859A1

  公开（公告）日：2012-06-20

  The invention relates to derivatives of the general formulae I and II to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts, or solvates which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts, or solvates thereof as adenosine receptor antagonists, in particular for the treatment of neurodegenerative disorders, e.g. stroke, amylotrophic lateral sclerosis, dementia, Alzheimer's disease, Parkinson's disease, ischemia/reperfusion injury, inflammation, and/or neurological disorder. The blockade of adenosine receptors could also be useful for other indications regarding the metabolism, e.g. diabetic retinopathy, diabetes mellitus, hyperbaric oxygen-induced retinopathy and/or obesity. Applications could also be the treatment of allergic diseases and autoimmune diseases, including mast cell degranulation, asthma, bronchoconstriction, pulmonary fibrosis, inflammatory or obstructive airways disease and/or chronic obstructive pulmonary disease (COPD). In addition, they could be used to treat cancer, e.g. proliferating tumor, cell proliferation disorders, angiogenesis, lung cancer, breast cancer, pancreatic cancer, thyroid cancer, skin cancer, vascular endothelial cancer, cancer of the central nervous system, esophageal cancer, cancer of the larynx, gastrointestinal cancer, colon cancer, colorectal cancer, rectal cancer, liver cancer, renal cancer, prostate cancer, bladder cancer, cervical cancer, ovarian cancer, endometrial cancer, melanoma, squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer selected from squamous cell carcinoma, adenocarcinoma, large cell carcinoma, adenosquam- ous carcinoma and/or undifferentiated carcinoma. The diseases associated with adenosine receptors are also diabetes, diarrhea, inflammatory bowel disease and/or gastrointestinal tract disorders. Adenosine receptor antagonists could be effective for treating a hepatic disease or condition for reducing fat deposition in the liver or fibrosis of the liver. The use of compounds of general formulae I and II can be associated with many applications e.g., scleroderm arthritis, atherosclerosis, urticaria, myocardial infarction, myocardial reperfusion after ischemia, vasodilation, hypertension, hypersensitivity, myocardial ischemia, heart attack and/or retinopathy of prematurity.

  本发明涉及具有通用公式I和II的衍生物，以及它们的制备方法，包含所述化合物的药物制剂以及/或可以从它们产生的生理上相容的盐或溶剂化物，以及所述化合物、盐或溶剂化物作为腺苷受体拮抗剂的药物用途，特别是用于治疗神经退行性疾病，例如中风、肌萎缩侧索硬化、痴呆、阿尔茨海默病、帕金森病、缺血/再灌注损伤、炎症和/或神经系统疾病。腺苷受体的阻断还可能对其他与代谢有关的适应症有益，例如糖尿病视网膜病变、糖尿病、高氧引起的视网膜病变和/或肥胖。应用还可能是治疗过敏性疾病和自身免疫性疾病，包括肥大细胞脱粒、哮喘、支气管收缩、肺纤维化、炎症性或阻塞性气道疾病和/或慢性阻塞性肺病（COPD）。此外，它们还可用于治疗癌症，例如增殖性肿瘤、细胞增殖障碍、血管生成、肺癌、乳腺癌、胰腺癌、甲状腺癌、皮肤癌、血管内皮癌、中枢神经系统癌症、食管癌、喉癌、胃肠癌、结肠癌、结直肠癌、直肠癌、肝癌、肾癌、前列腺癌、膀胱癌、宫颈癌、卵巢癌、子宫内膜癌、黑色素瘤、鳞状细胞癌、基底细胞癌、非小细胞肺癌（包括鳞状细胞癌、腺癌、大细胞癌、腺鳞癌和/或未分化癌）。与腺苷受体相关的疾病还包括糖尿病、腹泻、炎症性肠病和/或胃肠道的疾病。腺苷受体拮抗剂可能对治疗肝脏疾病或状况有效，用于减少肝脏脂肪沉积或肝脏纤维化。通用公式I和II的化合物的使用可以与许多应用相关，例如，硬皮病关节炎、动脉粥样硬化、荨麻疹、心肌梗死、缺血后心肌再灌注、血管扩张、高血压、过敏反应、心肌缺血、心脏病发作和/或早产儿视网膜病变。